New Herceptin early breast cancer regimens

Herceptin (trastuzumab) has had its licence for use in HER2-positive early breast cancer extended.

In addition to use following surgery, chemotherapy and radiotherapy, it is now also recommended in:

• combination with paclitaxel or docetaxel following adjuvant chemotherapy with doxorubicin and cyclophosphamide, or;
• combination with docetaxel and carboplatin.

In early breast cancer patients, cardiac monitoring should be performed before treatment initiation, every 3 months during treatment and every 6 months for 2 years from the last dose of Herceptin.

View Herceptin drug record

Further Information: Roche Products Ltd